Thalassaemia major: transfusion, iron chelation and what goes wrong
- Treatment and support
Children with thalassaemia major live on regular transfusions. The blood keeps them alive; the iron it brings slowly poisons the heart unless it is removed.
What it is
Transfusion-dependent thalassaemia (beta-thalassaemia major and some severe alpha and HbE forms) is treated with lifelong regular red cell transfusion from infancy. Transfusion corrects the anaemia and switches off the patient's own ineffective marrow. Because the body has no way to excrete iron, each transfusion adds iron that must be removed with chelating drugs. Survival now depends mostly on how well iron is controlled, especially in the heart.
What to know
- Transfusions are given every few weeks, aiming to keep the haemoglobin high enough before each one to suppress the patient's own marrow.
- Under-transfusion lets the marrow expand: facial and skull bone changes, fractures, a big spleen, extramedullary masses and more gut iron absorption.
- Each unit of red cells adds iron; overload damages the heart (failure, arrhythmia), liver (fibrosis, cirrhosis), and glands (delayed puberty, diabetes, hypothyroidism, low parathyroid).
- Three chelators are used: deferoxamine (slow infusion under the skin or into a vein), deferiprone (tablets several times a day) and deferasirox (once-daily tablets); they can be combined.
- Heart iron is measured by cardiac MRI (T2*); it can be high even when liver iron and ferritin look acceptable.
- Allogeneic stem cell transplant can cure; results are best in young children with a matched sibling. Gene therapy is approved in some countries, and luspatercept can lower transfusion needs in adults.
How it is done (and why)
- Confirm transfusion dependence (severe anaemia, failure to thrive) before starting a lifelong programme, usually in the first two years of life.
- Before the first transfusion: extended red cell phenotype or genotype, and hepatitis B vaccination.
- Give leukoreduced, phenotype-matched red cells on a regular schedule, adjusted to the pre-transfusion haemoglobin and growth.
- Start chelation once iron accumulates (after the first transfusions, guided by ferritin and liver iron), and choose the drug by age, iron site and side effects.
- Measure iron in the liver and heart by MRI where available, and intensify or combine chelation when heart iron rises.
- Watch growth, puberty and the glands yearly, and treat deficiencies as they appear.
- Consider splenectomy only when the spleen markedly increases transfusion needs; vaccinate beforehand.
The three iron chelators
| Feature | Deferoxamine | Deferiprone | Deferasirox |
|---|---|---|---|
| How given | Slow infusion under the skin or into a vein over hours | Tablets or liquid several times a day | Tablets once a day |
| Main toxicity | Hearing and vision damage, local reactions, Yersinia infection | Agranulocytosis (very low neutrophils), joint pain | Kidney and liver injury, gut upset |
| Must monitor | Hearing and eye checks | Neutrophil count very often; stop with fever | Creatinine, urine protein, liver tests |
| Strength | Long experience; intensive infusion for heart failure | Good at removing heart iron | Convenient; good adherence |
Risks and precautions
- Fever in a patient taking deferiprone needs an urgent neutrophil count: agranulocytosis can be fatal.
- Fever with abdominal pain or diarrhoea in a patient on deferoxamine suggests Yersinia infection; chelation is paused and antibiotics started.
- Heart failure from iron can appear suddenly in a young adult and is reversible only with very intensive chelation: it is an emergency.
- After splenectomy, patients face overwhelming infection and thrombosis; vaccines, fever plans and sometimes antibiotics are needed.
- Non-transfusion-dependent thalassaemia still loads iron from the gut, and needs monitoring for iron, thrombosis, pulmonary hypertension and leg ulcers.
Monitoring and next step
- Before each transfusion: haemoglobin and antibody screen; keep a record of the trend and of the yearly blood volume received.
- Ferritin regularly; liver iron by MRI and cardiac T2* by MRI at least yearly where available.
- On deferiprone: neutrophil count very often; on deferasirox: creatinine, urine protein and liver tests; on deferoxamine: hearing and eye checks.
- Yearly: growth and puberty, glucose, thyroid, calcium and parathyroid hormone, bone density in adolescents and adults.
- Viral screens (hepatitis B and C, HIV) at intervals in patients transfused for years.
Common traps
- Judging iron control by ferritin alone: it is affected by inflammation and liver damage, and the heart can be loaded while ferritin looks acceptable.
- Transfusing just enough to relieve symptoms: a low pre-transfusion haemoglobin lets the marrow expand and absorb more iron.
- Forgetting the neutrophil checks on deferiprone: it requires frequent neutrophil counts, and fever on it is an emergency.
- Treating non-transfusion-dependent thalassaemia as harmless: iron overload and thrombosis still develop.
Test yourself
Think of the answer, then tap the question to see it.
Why does a child with thalassaemia major who is under-transfused absorb more iron from food?
The expanded, ineffective marrow sends signals that suppress hepcidin, so the gut absorbs more iron even though the body is already overloaded.
A young adult with thalassaemia has an acceptable ferritin but becomes breathless. Which test do you need?
Cardiac MRI T2* and an echocardiogram: iron can load the heart while ferritin and liver iron look acceptable, and iron cardiomyopathy needs urgent intensive chelation.
A patient on deferiprone has a fever. What must be done first, and why?
An urgent neutrophil count and stopping the drug until it is known, because deferiprone can cause agranulocytosis and a febrile neutropenic patient can die of sepsis.
Why is splenectomy no longer routine in thalassaemia major?
Good transfusion keeps the spleen small, and splenectomy brings lifelong risks of overwhelming infection and thrombosis; it is kept for a spleen that clearly increases transfusion needs.
Elsewhere in DurgiPedia
- Thalassaemias: β and α
- Complications of transfusion
- Body iron balance
- Iron metabolism
- What the spleen filters: culling, pitting, iron; life without it
Connections
In Pharmacology5
Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.
Sources: Thalassemia (MedlinePlus, US National Library of Medicine, 2026); Beta thalassemia (MedlinePlus Genetics, US National Library of Medicine, 2026); DailyMed - DEFERIPRONE tablet, coated (DailyMed (U.S. National Library of Medicine), 2026); DailyMed - DEFERASIROX- deferasirox tablet, film coated (DailyMed (U.S. National Library of Medicine), 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
